darexaban + darexaban (double dose) + Acetyl Salicylic Acid + clopidogrel
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacodynamic Interaction
Conditions
Pharmacodynamic Interaction, Healthy Subjects
Trial Timeline
Apr 1, 2009 → Sep 1, 2009
NCT ID
NCT01409616About darexaban + darexaban (double dose) + Acetyl Salicylic Acid + clopidogrel
darexaban + darexaban (double dose) + Acetyl Salicylic Acid + clopidogrel is a phase 1 stage product being developed by Astellas Pharma for Pharmacodynamic Interaction. The current trial status is completed. This product is registered under clinical trial identifier NCT01409616. Target conditions include Pharmacodynamic Interaction, Healthy Subjects.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01409616 | Phase 1 | Completed |
Competing Products
10 competing products in Pharmacodynamic Interaction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| GP40141 + Nplate | GEROPHARM | Phase 1 | 25 |
| Darexaban + Acetyl Salicylic Acid (ASA) | Astellas Pharma | Phase 1 | 33 |
| darexaban + Naproxen | Astellas Pharma | Phase 1 | 33 |
| AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solution | AstraZeneca | Phase 1 | 33 |
| AZD9977 oral suspension + AZD9977 placebo oral suspension + Fludrocortisone, tablets + Eplerenone, tablets | AstraZeneca | Phase 1 | 33 |
| D961H + Omeprazole | AstraZeneca | Phase 1 | 33 |
| Dienogest (81150037) + Dienogest (81150231) + Dienogest (SH T00660A) + Dienogest (81150746) | Bayer | Phase 1 | 30 |
| 5 mg ACT-281959 prodrug formulation I (Group A) + 20 mg ACT-281959 prodrug formulation I (Group B) + ACT-281959 prodrug formulation I (Groups C to G doses to be defined) + ACT-281959 prodrug formulation II (Group G dose to be defined) + ACT-246475 (Group G dose to be defined) + Placebo (Groups A to F) | Idorsia | Phase 1 | 28 |
| Vamorolone + Eplerenone + Fludrocortisone | Santhera Pharmaceuticals | Phase 1 | 25 |
| VXA-A1.1 H1 Tablet Vaccine (small) + VXA-A1.1 H1 Tablet Vaccine (large) | Vaxart | Phase 1 | 25 |